Interestingly, data regard the use of very low u-hCG dose plus high-dose r-FSH bolus in IVF patients not at a high risk for OHSS, even if the presumed efficacy on OHSS incidence needs to be confirmed in other settings on larger study samples and in high-risk populations. This evidence concerns the gene BRD2 and ovarian hyperstimulation syndrome.